Toru Kumagai

6.7k total citations
156 papers, 3.1k citations indexed

About

Toru Kumagai is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Toru Kumagai has authored 156 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Pulmonary and Respiratory Medicine, 75 papers in Oncology and 35 papers in Molecular Biology. Recurrent topics in Toru Kumagai's work include Lung Cancer Treatments and Mutations (80 papers), Lung Cancer Research Studies (26 papers) and Cancer Genomics and Diagnostics (21 papers). Toru Kumagai is often cited by papers focused on Lung Cancer Treatments and Mutations (80 papers), Lung Cancer Research Studies (26 papers) and Cancer Genomics and Diagnostics (21 papers). Toru Kumagai collaborates with scholars based in Japan, United States and Germany. Toru Kumagai's co-authors include Kazumi Nishino, Fumio Imamura, Junji Uchida, Takako Inoue, Ichiro Kawase, Isao Tachibana, Takashi Kijima, Madoka Kimura, Tadashi Osaki and Mitsuhiro Yoshida and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Toru Kumagai

149 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Toru Kumagai Japan	32	1.4k	1.4k	1.1k	741	288	156	3.1k
James M. Kozlowski United States	37	1.3k 0.9×	1.7k 1.2×	1.8k 1.7×	816 1.1×	411 1.4×	84	4.1k
Colby L. Eaton United Kingdom	31	1.4k 1.0×	873 0.6×	1.5k 1.4×	648 0.9×	196 0.7×	80	2.9k
Jonathan M. Kurie United States	31	1.6k 1.1×	1.2k 0.8×	2.2k 2.1×	1.2k 1.6×	292 1.0×	73	4.0k
Adrie van Bokhoven United States	35	992 0.7×	1.6k 1.1×	2.5k 2.4×	1.1k 1.4×	312 1.1×	74	4.6k
Hisanori Uehara Japan	39	1.7k 1.2×	1.7k 1.2×	2.3k 2.2×	954 1.3×	719 2.5×	135	5.1k
Pernilla Wikström Sweden	38	1.1k 0.8×	1.9k 1.4×	2.3k 2.1×	1.3k 1.7×	768 2.7×	105	4.5k
Robert D. Loberg United States	34	2.1k 1.5×	920 0.7×	1.6k 1.5×	832 1.1×	1.0k 3.6×	59	4.1k
David J. Mulholland United States	28	1.2k 0.8×	1.2k 0.9×	2.9k 2.7×	937 1.3×	329 1.1×	50	4.4k
Timothy F. Burns United States	33	1.6k 1.2×	736 0.5×	2.7k 2.6×	794 1.1×	631 2.2×	121	4.0k
R. Ilona Linnoila United States	36	1.9k 1.3×	1.3k 1.0×	1.7k 1.6×	539 0.7×	149 0.5×	64	4.1k

Countries citing papers authored by Toru Kumagai

Since Specialization

Citations

This map shows the geographic impact of Toru Kumagai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toru Kumagai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toru Kumagai more than expected).

Fields of papers citing papers by Toru Kumagai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toru Kumagai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toru Kumagai. The network helps show where Toru Kumagai may publish in the future.

Co-authorship network of co-authors of Toru Kumagai

This figure shows the co-authorship network connecting the top 25 collaborators of Toru Kumagai. A scholar is included among the top collaborators of Toru Kumagai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toru Kumagai. Toru Kumagai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yoshida, Tatsuya, Toru Kumagai, Ryo Toyozawa, et al.. (2023). Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial. Cancer Science. 114(9). 3698–3707. 7 indexed citations

Inoue, Satoko, Mayako Uchida, Keiko Fujita, et al.. (2023). Efficacy and safety of mycophenolate mofetil in treating immune‐related hepatitis induced by immune checkpoint inhibitor use: A retrospective study. JGH Open. 7(2). 87–97. 9 indexed citations

Kunimasa, Kei, Kazumi Nishino, Yoshiharu Sato, et al.. (2022). Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC. Scientific Reports. 12(1). 13544–13544. 5 indexed citations

Sugawara, Shunichi, Masashi Kondo, Toshihide Yokoyama, et al.. (2022). Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study. International Journal of Clinical Oncology. 27(12). 1828–1838. 5 indexed citations

Kunimasa, Kei, Toru Oka, Satoshi Hara, et al.. (2020). Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction. Lung Cancer. 153. 186–192. 24 indexed citations

Kunimasa, Kei, Toru Oka, Makiko Oboshi, et al.. (2020). Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib. JACC CardioOncology. 2(1). 1–10. 58 indexed citations

Inoue, Takako, Tatsuya Nishikawa, Kei Kunimasa, et al.. (2020). Infectious pericarditis caused by Gemella sanguinis induced by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA): A case report. Respiratory Medicine Case Reports. 30. 101057–101057. 6 indexed citations

Nishio, Makoto, Tatsuya Yoshida, Toru Kumagai, et al.. (2020). Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. Journal of Thoracic Oncology. 16(3). 452–463. 47 indexed citations

Sugawara, Shunichi, Naoki Inui, Masashi Kanehara, et al.. (2019). Multicenter, placebo‐controlled, double‐blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Cancer. 125(22). 4076–4083. 8 indexed citations

10.

Kunimasa, Kei, Masashi Kimura, Tomio Inoue, et al.. (2019). EP1.14-08 Irreversible Severe Cardiotoxicities Except for QTc Interval Prolongation Associated with Osimertinib. Journal of Thoracic Oncology. 14(10). S1034–S1035.

11.

Kumagai, Toru, Yasuhiko Tomita, Shin‐ichi Nakatsuka, et al.. (2018). HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1. Thoracic Cancer. 9(4). 466–471. 9 indexed citations

12.

Kimura, Madoka, Hiroko Endo, Takako Inoue, et al.. (2015). Analysis of ERBB Ligand-Induced Resistance Mechanism to Crizotinib by Primary Culture of Lung Adenocarcinoma with EML4-ALK Fusion Gene. Journal of Thoracic Oncology. 10(3). 527–530. 23 indexed citations

13.

Takahashi, Ryo, Haruhiko Hirata, Isao Tachibana, et al.. (2011). Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung. Clinical Cancer Research. 18(1). 220–228. 78 indexed citations

14.

Taniguchi, Kazuya, Junji Uchida, Kazumi Nishino, et al.. (2011). Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas. Clinical Cancer Research. 17(24). 7808–7815. 250 indexed citations

15.

Suzuki, Mayumi, Isao Tachibana, Yoshito Takeda, et al.. (2009). Tetraspanin CD9 Negatively Regulates Lipopolysaccharide-Induced Macrophage Activation and Lung Inflammation. The Journal of Immunology. 182(10). 6485–6493. 70 indexed citations

16.

Nagatomo, Izumi, Toru Kumagai, Tadahiro Yamadori, et al.. (2007). Gefitinib-Sensitive EGFR Lacking Residues 746–750 Exhibits Hypophosphorylation at Tyrosine Residue 1045, Hypoubiquitination, And Impaired Endocytosis. DNA and Cell Biology. 26(3). 178–185. 14 indexed citations

17.

Furuuchi, Keiji, Alan Berezov, Toru Kumagai, & Mark I. Greene. (2007). Targeted Antireceptor Therapy with Monoclonal Antibodies Leads to the Formation of Inactivated Tetrameric Forms of ErbB Receptors. The Journal of Immunology. 178(2). 1021–1029. 20 indexed citations

18.

Yoneda, Tsutomu, Toru Kumagai, Izumi Nagatomo, et al.. (2006). The Extracellular Domain of p185 ^c-neu Induces Density-Dependent Inhibition of Cell Growth in Malignant Mesothelioma Cells and Reduces Growth of Mesothelioma In Vivo. DNA and Cell Biology. 25(9). 530–540. 1 indexed citations

19.

Nagatomo, Izumi, Toru Kumagai, Tadahiro Yamadori, et al.. (2006). The Gefitinib-Sensitizing Mutant Epidermal Growth Factor Receptor Enables Transformation of a Mouse Fibroblast Cell Line. DNA and Cell Biology. 25(4). 246–251. 10 indexed citations

20.

Kida, Hiroshi, Mitsuhiro Yoshida, Koji Inoue, et al.. (2004). Protective effect of IL-6 on alveolar epithelial cell death induced by hydrogen peroxide. American Journal of Physiology-Lung Cellular and Molecular Physiology. 288(2). L342–L349. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact